{"entity":{"id":"rejuv-age-telomere-length","kind":"technology","name":"Telomere length after treatment","aka":[],"tldr":"Telomeres are the caps on chromosomes that shorten each time a cell divides. They are the oldest and best known measure of cellular ageing, and the one with the least to show for itself in cancer survivors so far: the measurements exist, the associations are inconsistent, and nothing follows from a result.","summary":"Telomere length is usually measured in leukocytes, which makes it a measure of how much the blood compartment has divided rather than of the body as a whole. In a nested case-control study within the Childhood Cancer Survivor Study, 46 radiation-exposed survivors who developed a thyroid subsequent malignant neoplasm were matched to 46 who did not. Cases had shorter median lymphocyte telomere length in three of four leukocyte subsets, were more likely to have natural killer cell telomere length below the 10th percentile (P = 0.01), and were 2.8 times more likely to have naive T-cell telomere length below the 10th percentile (95% CI 1.07 to 8.78).\n\nAgainst that, in 1,413 long-term survivors of childhood cancer assessed with a full neuropsychological battery, mean leukocyte telomere length was not associated with neurocognitive function, while two epigenetic clocks were. The two findings are not contradictory, but together they show the limits of the measure: telomere length in blood picks up some of what treatment did to the haematopoietic compartment and little of what it did elsewhere.\n\nNo intervention has been shown to lengthen telomeres in people in a way that changes health, and products sold on that claim are selling a measurement, not an outcome. Telomerase is also the enzyme most cancers reactivate, which is a reason for caution about anything that promises to switch it on.","status":"emerging","asOf":"2026-10-02","wikipedia":"https://en.wikipedia.org/wiki/Telomere","links":[{"label":"Gramatges et al., Short NK- and naive T-cell telomere length is associated with thyroid cancer in childhood cancer survivors (Cancer Epidemiol Biomarkers Prev 2022)","url":"https://doi.org/10.1158/1055-9965.EPI-21-0791"},{"label":"Dong et al., Epigenetic age acceleration, telomere length, and neurocognitive function in long-term survivors of childhood cancer (Nat Commun 2025)","url":"https://doi.org/10.1038/s41467-025-65664-5"}],"tags":["rejuvenation","survivorship","biological-ageing","biomarker"],"related":["rejuv-age-epigenetic-clocks","rejuv-age-clonal-haematopoiesis-after-therapy","rejuv-frontier-what-works"],"cancers":[],"sections":["rejuvenation","supportive-care"],"technologies":["survivorship-care-plan"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["telomere-maintenance"],"terms":["late-effects"],"trials":[],"people":[],"bottlenecks":["b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"principle":"Telomeres shorten with each replication and with oxidative stress; below a threshold the cell arrests or dies. Cytotoxic therapy destroys dividing haematopoietic cells and forces the survivors to divide more to repopulate the marrow, so the blood compartment of a survivor has a replicative history longer than the calendar suggests.","strengths":["Long-established measure with standardised assays such as flow-FISH","Matched case-control design within a large survivor cohort","Biologically interpretable in the blood compartment, where the replicative stress is"],"limitations":["Measures blood, not the tissues most people mean by ageing","Not associated with neurocognitive outcome in the largest survivor study to test it","No intervention lengthens telomeres in people to any demonstrated benefit, and telomerase is reactivated in most cancers"]},"route":"/technologies/rejuv-age-telomere-length/","neighbours":{"technology":[{"id":"rejuv-age-clonal-haematopoiesis-after-therapy","kind":"technology","name":"Clonal haematopoiesis after cancer treatment","route":"/technologies/rejuv-age-clonal-haematopoiesis-after-therapy/"},{"id":"rejuv-age-epigenetic-clocks","kind":"technology","name":"Epigenetic age after cancer treatment","route":"/technologies/rejuv-age-epigenetic-clocks/"},{"id":"survivorship-care-plan","kind":"technology","name":"Survivorship care and late-effects surveillance","route":"/technologies/survivorship-care-plan/"},{"id":"rejuv-frontier-what-works","kind":"technology","name":"What actually works after treatment","route":"/technologies/rejuv-frontier-what-works/"}],"section":[{"id":"rejuvenation","kind":"section","name":"Recovery & Rejuvenation","route":"/fronts/rejuvenation/"},{"id":"supportive-care","kind":"section","name":"Supportive Care & Survivorship","route":"/fronts/supportive-care/"}],"pathway":[{"id":"telomere-maintenance","kind":"pathway","name":"Telomere maintenance & replicative immortality","route":"/pathways/telomere-maintenance/"}],"term":[{"id":"late-effects","kind":"term","name":"Late effects and survivorship toxicity","route":"/terms/late-effects/"}],"bottleneck":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"}]}}